Figma Shares Indicated To Open $95/$100
John A. McCoy Jr., Vice President and Controller at Abbott Laboratories (NYSE:ABT), recently sold 562 shares of the company’s common stock. The transaction, dated March 3, 2025, was executed at an average price of $138.17 per share, amounting to a total of $77,651. Following this sale, McCoy holds 21,061 shares directly.
Additionally, on February 28, 2025, McCoy disposed of 1,096 shares as part of a transaction priced at $135.87 per share, resulting in a total value of $148,913. This transaction was part of a routine disposition of shares to cover tax obligations associated with the vesting of restricted stock units. InvestingPro analysis indicates the stock is currently in overbought territory, with 13 additional exclusive insights available to subscribers.
McCoy also maintains an indirect holding of 57 shares in the Abbott Laboratories Stock Retirement Trust as of the end of February. The company has demonstrated strong momentum with a 22.86% return over the past six months, though current valuations suggest the stock may be slightly overvalued.
In other recent news, Cadrenal Therapeutics has announced a collaboration with Abbott to conduct a pivotal clinical trial for their drug tecarfarin. This partnership aims to enhance the treatment for patients with left ventricular assist devices (LVADs) by leveraging Abbott’s expertise from their HeartMate 3™ LVAD trials. Meanwhile, Abbott Laboratories has seen several analyst firms adjust their price targets following updates in the company’s financial outlook. Barclays (LON:BARC) raised its price target to $158, citing Abbott’s revised earnings estimates and growth guidance despite challenges from foreign exchange rates and tax rates. Bernstein also increased its target to $138, highlighting strong performance in Abbott’s Medical (TASE:BLWV) Devices segment, particularly in Continuous Glucose Monitoring and Structural Heart products. Additionally, UBS raised its price target to $148, maintaining a positive outlook based on Abbott’s financial guidance for fiscal year 2025. These developments reflect a broader confidence in Abbott’s growth potential and strategic direction in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.